Yours is a complete distortion - right on schedule. Are you trying to do 'damage control'? Then stop causing more damage.
The article says VACCINATED plasma is not helpful. They want convalescent plasma from UNVACCINATED people.
I think it was found that convalescent plasma from actual COVID-19 disease survivors was not particularly effective.
………………………………………………………………………
Yours is a complete distortion - right on schedule. Are you trying to do ‘damage control’? Then stop causing more damage.
The article says VACCINATED plasma is not helpful. They want convalescent plasma from UNVACCINATED people.
********************************************************************
Oh, you Strange-Brew-Crewers and your campaigns of misinformation. Convalescent plasma is really NOT particularly effective but collecting it from recovered COVID-19 patients does deliver the American Red Cross and other collectors a whole lot of federal dollars. They get $600 - $800 a unit for collected covid product, compared with the $100 price for a regular unit of fresh, frozen plasma.
https://abcnews.go.com/Health/convalescent-plasma-demand-caveats/story?id=76611725
EXTRACT FOLLOWS:
The treatment that infuses blood plasma from recovered covid patients into people newly infected in hopes of boosting their immune response has not lived up to early hype. Some high-profile clinical trials have shown disappointing results. Demand from hospitals for the antibody-rich plasma has plunged. After a year of large-scale national efforts to recruit recovered covid patients as donors and the collection of more than 500,000 units of covid convalescent plasma, known as CCP, some longtime advocates of the therapy say they’re now pessimistic about its future.
“I fear the CCP train has left the station,” said Dr. Michael Busch, director of the Vitalant Research Institute, one of the largest blood-center based transfusion medicine research programs in the U.S. “We created all this enthusiasm, and then these studies came out and they say this stuff didn’t work in the first place.”…
…Enthusiasm faded in recent weeks following two serious setbacks: A large federal clinical trial, dubbed C3PO, testing the use of convalescent plasma in high-risk patients who came to an emergency room with mild to moderate covid symptoms was halted late last month after researchers concluded that, while the infusions caused no harm, they were unlikely to benefit patients. That same week, a pooled analysis of 10 convalescent plasma studies, published in JAMA, found no clear benefit.
In January, the FDA scaled back the emergency authorization of convalescent plasma, limiting its use to hospitalized covid patients early in the course of the disease and those with medical conditions that impair immune function. The agency also said that only plasma with high concentrations of virus-fighting antibodies could be used after May 31….
… Further complicating matters, federal contracts worth $646 million that paid U.S. blood centers to collect covid convalescent plasma are about to expire, prompting centers nationwide to reconsider whether the complicated process of collecting the plasma is still worth the work. Given the added complexity, blood centers have been reimbursed $600 to $800 a unit for the covid product, compared with the $100 price for a regular unit of fresh, frozen plasma.
“We’re not getting orders,” said Dr. Louis Katz, chief medical officer at the Mississippi Valley Regional Blood Center in Davenport, Iowa. “I don’t want to collect a product that is not going to get used and will cost me more money.”